Madrigal Pharmaceuticals




MarketCap US

US United States


Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.


Madrigal Pharmaceuticals was founded in 1992, and since then the company has been developing drug candidates that target metabolic and cardiovascular diseases, as well as other conditions. The company has developed a pipeline of potential treatments for its targeted conditions consisting of small molecules, monoclonal antibodies, and other biologics.

Madrigal Pharmaceuticals is committed to discovering, developing, and commercializing innovative and safe therapeutics to improve the lives of people living with metabolic and cardiovascular diseases.

Madrigal Pharmaceuticals is advancing our mission to develop safe and effective therapeutics by creating transformative treatments that will meaningfully improve patients' lives and reduce the burden of disease.

Key Team

Mr. Brian J. Lynch J.D. (Sr. VP & Gen. Counsel)

Mr. Remy Sukhija (Sr. VP & Chief Commercial Officer)

Dr. Kianoush Motesharei Ph.d. (Sr. VP of Bus. & Corp. Devel.)

Mr. Thomas W. Hare (Sr. VP of Clinical Management)

Mr. Edward Chiang (Sr. VP of Clinical & Technical Operations)

Dr. Robert E. Waltermire Ph.D. (Chief Pharmaceutical Devel. Officer)

Dr. Stephen Dodge M.B.A., Pharm.D. (Sr. VP of Global Medical Affairs)

Recognition and Awards
Madrigal Pharmaceuticals has been recognized for its efforts to advance treatments for metabolic and cardiovascular diseases. The company has received numerous industry awards, including the Prix Galien USA Award for Best Biotechnology Product for MGL-3196.

Madrigal Pharmaceuticals
Leadership team

Dr. Paul A. Friedman M.D. (Chairman & CEO)

Dr. Rebecca A. Taub M.D. (Founder, Chief Medical Officer, Pres of R&D and Director)

Mr. Alex G. Howarth (Sr. VP & CFO)

Products/ Services
Biotechnology, Medical Device, Pharmaceutical
Number of Employees
50 - 100
Washington, Pennsylvania, United States
Company Registration
SEC CIK number: 0001157601
Traded as
Fri Feb 23 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium